Lingfang Wang

机构：Jiang Xi Institute for Drug Control · ORCID：0000-0002-9002-3657

发表论文 219 篇 · 总被引 3267 次 · h-index 34

代表论文

• CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer (2024 · Drug Resistance Updates · 被引 22)
• Human urine stem cells protect against cyclophosphamide-induced premature ovarian failure by inhibiting SLC1A4-mediated outflux of intracellular serine in ovarian granulosa cells (2025 · Cellular & Molecular Biology Letters · 被引 13)
• Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells (2025 · Journal of Advanced Research · 被引 11)
• Myeloid but not hepatocytic CD38 is a key driver for hepatic ischemia/reperfusion injury (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Endothelial CD38-induced endothelial-to-mesenchymal transition is a pivotal driver in pulmonary fibrosis (2024 · Cellular and Molecular Life Sciences · 被引 8)
• The biomarker potential of circPOLD1 and its binding protein YBX1 in cervical carcinogenesis (2025 · Journal of Translational Medicine · 被引 7)